AstraZeneca’s “Began research on the efficacy of its own vaccine against mutant virus”
––
▲ AstraZeneca Corona 19 Vaccine
AFP Yonhap News
–
–
AstraZeneca, a British pharmaceutical company that Korea has only signed a contract with, announced that its Corona 19 (new coronavirus infection) vaccine will be effective in preventing the variant virus discovered this time, Reuters reported on the 22nd (local time). Recently discovered in the UK, called’B.1.1.7′, the infectivity of this variant is up to 70% higher, and it is analyzed that it can be easily transmitted to children.
AstraZeneca said, “(The company’s vaccine candidate) AZD1222 contains the genetic material of the protein spike that is raised in the coronavirus (SARS-CoV-2).” It doesn’t seem to have changed.”
He emphasized that it has begun a study on the efficacy of its vaccine against this strain of virus. “With AZD1222, the body’s immune system is trained to recognize different parts of the protein spike,” AstraZeneca said. “This is a way to get rid of the virus later when exposed.”
AstraZeneca, who developed the Corona 19 vaccine in partnership with researchers at Oxford University in the UK, announced earlier this month that its vaccine prevention effect was 62-90%.
Reporter Kang Ju-ri [email protected]
–
